CTOs on the Move

Decibel Therapeutics

www.decibeltx.com

 
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.decibeltx.com
  • 1325 Boylston Street Suite 500
    Boston, MA USA 02215
  • Phone: 617.370.8701

Executives

Name Title Contact Details
Nathan Doyle
 Director of Informatics and IT Profile

Funding

Decibel Therapeutics raised $55M on 06/19/2018
Decibel Therapeutics raised $82M on 11/09/2020

Similar Companies

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pierrel Research

Pierrel Research is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alberta Conservation Association

Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redpin Therapeutics

Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease